From the Barry and Judy Silverman College of Pharmacy…
October 2023 Research Highlights reported by the Barry and Judy Silverman College of Pharmacy.
Benedict C. Albensi Ph.D., Professor and Chair of the Barry and Judy Silverman College of Pharmacy, is now ranked in the TOP 20 in Florida for his number of publications on Alzheimer’s disease (last 10 years). This is according to Expertscape.com in spite of the list not being complete for 2023 (4 papers not showing yet ). For more information see the link at: https://lnkd.in/eAtyN8k3 . For a link to Dr. Albensi’s papers & presentations go to: https://lnkd.in/eMfCVut.
Developing Personalized Preventative Measures to Fight Dementia
Dr. Albensi is working as a Co-Investigator on a new grant from the National Institutes of Health (NIH). The grant, titled “Effects of mild traumatic brain injury in a mouse model of cerebral amyloid angiopathy (CAA).” CAA is a type of dementia like Alzheimer’s disease. Principal Investigator Lisa Robison Ph.D., and fellow Co-Investigator William Kochen, Ph.D., both from the College of Psychology are working to gather more information about how even mild brain injuries can increase dementia risk and what interventions, if any, can affect the progress of the disease. The project, totaling more than $300,000 investigates damage to the brain’s blood vessels by CAA, a toxic protein, as a potential link.
Discovery of a Compound (F16) with a Promise for Treatment of Glioblastoma
Appu Rathinavelu Ph.D., executive director of the Rumbaugh-Goodwin Institute for Cancer Research, and professor at the Silverman College of Pharmacy, along with his team discovered and patented a compound – code-named F16 – which is showing promising results in pre-clinical testing for the treatment of Glioblastoma. The Institute, in consultation with the university’s Office of Research and Technology Transfer, have engaged a well-known Clinical Research Organization to externally validate these findings and prepare for Investigational New Drug (IND) filing with FDA.
Robert Speth, Ph.D., Professor in Pharmaceutical Sciences recently had a correspondence article published in the #2 ranked biomedical journal, The New England Journal of Medicine. The article brought up many interesting points in relation to the original publication by Bhandari et al. titled, “Renin-Angiotensin System Inhibition in Advanced Chronic Kidney Disease.”